✦ LIBER ✦

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

✍ Scribed by Marin, D; Gabriel, I H; Ahmad, S; Foroni, L; Lavallade, H de; Clark, R; O'Brien, S; Sergeant, R; Hedgley, C; Milojkovic, D; Khorashad, J S; Bua, M; Alsuliman, A; Khoder, A; Stringaris, K; Cooper, N; Davis, J; Goldman, J M; Apperley, J F; Rezvani, K

Book ID: 119980278
Publisher: Nature Publishing Group
Year: 2011
Tongue: English
Weight: 349 KB
Volume: 26
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2011.180

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EUTOS score predicts survival and cytoge

EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

✍ Tao, Zhongfei; Liu, Bingcheng; Zhao, Yaozhong; Wang, Ying; Zhang, Rongli; Han, M 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Different kinetic patterns of BCR-ABL tr

Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response

✍ Y. Z. QIN; Y. R. LIU; H. H. ZHU; J. L. LI; G. R. RUAN; Y. ZHANG; Q. JIANG; H. JI 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

Efficacy and safety of imatinib in patie

Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α

✍ Susan Branford; Timothy Hughes; Alvin Milner; Rachel Koelmeyer; Anthony Schwarer 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN‐α‐responsive patients can experience further improvements with imatinib has not

The Achievement of a 3-Month Complete Cy

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

✍ Jabbour, Elias; Kantarjian, Hagop; Ghanem, Hady; O'Brien, Susan; Quintas-Cardama 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 305 KB

Long-term survival estimates for imatini

Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Kevin J. Anstrom; Shelby D. Reed; Andrew S. Allen; G. Alastair Glendenning; Kevi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

Functional polymorphism of CYP2B6 G15631

Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib

✍ Kassogue, Yaya; Quachouh, Meryem; Dehbi, Hind; Quessar, Asma; Benchekroun, Said; 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 282 KB